The NOTCH gene was identified approximately 110 years ago. Classical studies have
revealed that NOTCH signaling is an evolutionarily conserved pathway. NOTCH receptors …

Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective
therapies are urgently needed. Several lines of evidence, from SCLC primary human …

Background Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor
prognosis and treatment options are scarce. Immunotherapy has shown robust clinical …

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A,-N, and-P …

Introduction Recent studies have identified subtypes of small cell lung carcinoma (SCLC)
defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional …

Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy
resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved …

Introduction Pembrolizumab has shown clinical benefit in patients with previously treated
recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 …

Small-cell lung cancer (SCLC) encounters up 15% of all lung cancers, and is characterized
by a high rate of proliferation, a tendency for early metastasis and generally poor prognosis …

Purpose: Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high
relapse rate, limited therapeutic options, and poor prognosis. We investigated the antitumor …

Metastasis is a major cause of morbidity and mortality in cancer patients. However, the
molecular and cellular mechanisms underlying the ability of cancer cells to metastasize …